Clinical Trials

PARTICIPATE IN CLINICAL RESEARCH FOR NEUROLOGICAL DISORDERS IN BATON ROUGE, LOUISIANA

The NeuroMedical Center is dedicated to the advancement of new and better treatment strategies for our patients and all who suffer from neurological disorders. Our Clinical Research Program located on the 4th floor of The NeuroMedical Center Clinic is actively pursuing accelerated research that may eventually lead to new, or more effective treatments for neurological disease.  For more information on our clinical studies, or to find out how to enroll, please contact our study coordinator, Crystal Whiddon at (225) 761-2569 or by emailing crystal.whiddon@intrafusion.com

ENROLLING STUDIES AT THE NEUROMEDICAL CENTER

The following studies are open for enrollment:

 

ATARA BIO
Protocol: ATA188-MS-101

  • TITLE: An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis
  • To learn more about this study, please visit www.clinicaltrials.gov
    • Please refer to this study by its identifier (NCT number): NCT03283826

Genentech ENSAMBLE PLUS

Protocol: MA30143

  • TITLE: An  Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing-Remitting Multiple Sclerosis
  • To learn more about this study, please visit www.clinicaltrials.gov
    • Please refer to this study by its identifier (NCT number): NCT03085810

Abbvie
Protocol: M18-918

  • TITLE: A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
  • To learn more about this study, please visit www.clinicaltrials.gov
    • Please refer to this study by its identifier (NCT number): NCT03737851

Enterin
Protocol: ENT-01-030

  • TITLE: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson’s Disease Related Constipation (KARMET)
  • To learn more about this study, please visit www.clinicaltrials.gov
    • Please refer to this study by its identifier (NCT number): NCT03781791

PENDING STUDIES AT THE NEUROMEDICAL CENTER

The following studies at The NeuroMedical Center are pending, and we will begin our participant recruitment process shortly. Please check back soon for study information and eligibility requirements.

  1. Multiple Sclerosis– Novartis COMB157G2399
  2. Trigeminal Neuralgia– Biogen 802NP301

ACTIVE STUDIES AT THE NEUROMEDICAL CENTER

The following clinical trials are currently active at The NeuroMedical Center.  Enrollment is closed:

  1. Genentech ENSEMBLE
    Protocol: MA30143

    • TITLE: An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple Sclerosis.
  2. Novartis
    Prorocol: COMB157G2301 (ASCLEPIOS I)

    • TITLE: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis

COMPLETED STUDIES AT THE NEUROMEDICAL CENTER

These studies have been completed at The NeuroMedical Center. Click on a study to view study details and any available results.

Multiple Sclerosis – SUN Pharma Advanced Research Company Ltd. (SPARC) CLR_09_21
A Placebo-Controlled Randomized Withdrawal Evaluation of the Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects with Spasticity Due to Multiple Sclerosis.

View Details >

Multiple Sclerosis – Sun Pharma Advanced Research Company Ltd. (SPARC) CLR_11_04
Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis.

View Details >

Parkinson’s Disease Civitas Therapeutics, Inc – CVT-301-004
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients with Motor Response Fluctuations (OFF Phenomena).

View Details >

Dystonia – Revance Therapeutics, Inc. RT002-CL005
A Phase 2, Open-label, Dose-escalating Study to Evaluate the Safety and Preliminary Efficacy of RTT150 for Injection in Isolated Cervical Dystonia.

View Details>

Multiple Sclerosis – Alkermes, Inc. ALK8700-A301
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis.

View Details >

Chronic Migraine – Allergan GMA-US-NEU-0206
A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of BOTOX® and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine.

View Details >

Parkinson’s Disease – Sunovion CTH-201
A Cardiac Safety Study of an Investigational Drug to See How it Affects the Heart in People with Parkinson’s Disease Complicated by Motor Fluctuations “OFF” Episodes.

View Results >

Parkinson’s Disease – Civitas Therapeutics, Inc. CVT-301-004E
A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson’s disease Patients with Motor Response Fluctuations (OFF Phenomena).

View Results >


HOW OUR PATIENTS BENEFIT IN CLINICAL TRIALS

Clinical trials at The NeuroMedical Center offer participants the opportunity to receive the latest developments and therapies only available in trial studies while they actively contribute to medical research. Participants are closely monitored by and provided care from a group of experienced physicians, lab technicians, and health professionals. Every volunteer is vital for the continuation of our neurological studies and our ongoing efforts for more information to improve medical care. People who take part in clinical studies gain more insight and knowledge of their condition and treatment. To most of our participants, the new knowledge gives them a lot of hope for future recovery.  Taking part in a clinical research study is an important decision and one you may want to discuss with your family or primary doctor. If you are interested in learning more about pending, active, and completed clinical trials, please visit ClinicalTrials.gov.

For more information on Clinical Trials at The NeuroMedical Center, or to find out how to enroll, please contact our study coordinator:

Crystal Whiddon

 (225) 761-2569 

crystal.whiddon@intrafusion.com